rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

BAKER BROS. ADVISORS LP

Director and 10% owner

Company insider

Files Form 4 as: Director and 10% owner, Incyte; Director and 10% owner, Kodiak Sciences; Director and 10% owner, BeOne Medicines; Director and 10% owner, Replimune Group; Other, Celcuity; Director, vTv Therapeutics; Director and 10% owner, Kymera Therapeutics; Director, Madrigal Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
670
Buys
58
Sells
15
Bought
$1.3B
Sold
$359.1M
Companies
30
Companies where not an officer
30
First trade
4 May 2012
Last trade
30 Sep 2026
Last filed
2 Oct 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
INCY IncyteDirector, 10% owner · Life-science tools · last 30 Sep 20261 buy · 0 sells
KOD Kodiak SciencesDirector, 10% owner · Biotechnology · last 29 Sep 202611 buys · 0 sells
ONC BeOne MedicinesDirector, 10% owner · Biotechnology · last 14 Sep 20262 buys · 1 sell
REPL Replimune GroupDirector, 10% owner · Biotechnology · last 11 Aug 20260 buys · 0 sells
CELC CelcuityOther · Biotechnology · last 14 Jul 20260 buys · 1 sell
VTVT vTv TherapeuticsDirector · Biotechnology · last 26 Jun 20260 buys · 0 sells
KYMR Kymera TherapeuticsDirector, 10% owner · Biotechnology · last 24 Jun 20260 buys · 0 sells
MDGL Madrigal PharmaceuticalsDirector · Pharmaceuticals · last 17 Jun 20262 buys · 0 sells
PRLD Prelude TherapeuticsDirector, 10% owner · Biotechnology · last 9 Jun 20260 buys · 0 sells
DNLI Denali TherapeuticsDirector · Biotechnology · last 3 Jun 20260 buys · 0 sells
ACAD ACADIA PharmaceuticalsDirector, 10% owner · Pharmaceuticals · last 29 May 20263 buys · 0 sells
KNSA Kiniksa Pharmaceuticals InternationalDirector, 10% owner · Biotechnology · last 29 May 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
104Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Sep 2026filed 2 Oct 2026INCY IncyteLife-science toolsSEC FORM 4 Code A—322 at $0.00filing
30 Sep 2026filed 2 Oct 2026INCY IncyteLife-science toolsSEC FORM 4 Code A—322 at $0.00filing
29 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$52K619 at $84.24filing
29 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$875K10,381 at $84.24filing
29 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$102K1,195 at $85.40filing
29 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$1.7M20,031 at $85.40filing
29 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$7,21484 at $85.89filing
29 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$122K1,416 at $85.89filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$52K856 at $61.21filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$361K5,382 at $67.10filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$11K154 at $68.37filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$177K2,585 at $68.37filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$161K2,331 at $68.96filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$2.7M39,066 at $68.96filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$75K1,056 at $71.48filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$1.3M17,698 at $71.48filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$1.2M16,641 at $72.39filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$20.2M278,978 at $72.39filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$343K4,696 at $73.08filing
28 Sep 2026filed 30 Sep 2026KOD Kodiak SciencesBiotechnologySEC FORM 4 Bought$878K14,344 at $61.21filing

The newest 500 lines are listed; the numbers count every line.

News

BeOne Medicines (NASDAQ:ONC) Price Target Raised to $420.00ONC · tickerreport.com · 10 Oct 2026

0 headlines in the last 90 days name BAKER BROS. ADVISORS LP; 1 article from the last 14 days about the 3 companies they traded most, at most three about any one of them.

Sectors

Health Care32
Not placed41

Buys in green, sells in red, by the company’s sector.

Related people

Xiaodong WangDirector and Other role · Director and Other at BeOne Medicines, filing Form 4 there in the last year
Leo FurchtDirector · Director at Celcuity, filing Form 4 there in the last year
Lee HeesonEVP, Head of Incyte Intl · EVP, Head of Incyte Intl at Incyte, filing Form 4 there in the last year
David W. GryskaDirector · Director at Celcuity, filing Form 4 there in the last year
Paul J. ClancyDirector · Director at Incyte, filing Form 4 there in the last year
Chan Henry LeeSVP, General Counsel · Also traded ONC in the last 90 days
Pablo J. CagnoniPresident, Global Head of R&D · Also traded INCY in the last 90 days
William John SiboldPresident and CEO · Also traded MDGL in the last 90 days